Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715175 | 0.85 | MAPT (0.61) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4713652 | 0.84 | MAPT (0.60) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4717304 | 0.82 | LMNA (0.60) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4716218 | 0.82 | LMNA (0.62) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4715393 | 0.81 | LMNA (0.62) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4715332 | 0.79 | LMNA (0.59) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4716118 | 0.78 | MAPT (0.62) | MAPTLMNAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL4715796 | 0.78 | MAPT (0.65) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL4712690 | 0.77 | LMNA (0.57) | MAPTLMNAKDM4ETSHRKMT2A | |
| SCHEMBL4714178 | 0.77 | LMNA (0.57) | MAPTLMNAKDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | MAPT 1753/4885LMNA 4722/4885KDM4E 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.